Cassava Sciences Reports Top-Line Results Of Two-Year Clinical Safety Study Of Simufilam, Investigational Oral Drug For Treatment Of Alzheimer's Disease

Moomoo 24/7 ·  Feb 7 09:18
  • ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer's Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.
  • Mild Alzheimer's Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24.
  • Oral Simufilam Safe, Well-Tolerated.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment